Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasms 2Myocardial Reperfusion Injury 2Cardiotoxicity 2Vomiting 1Uveal Melanoma 1Thrombosis 1Substance Withdrawal Syndrome 1Retinal Diseases 1Reperfusion Injury 1Pain, Postoperative 1Opioid-Related Disorders 1Nausea 1Melanoma 1Macular Degeneration 1Lymphoma, Follicular 1Lung Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Choroid Diseases 1Breast Neoplasms 1

Interventions

Carboplatin 340Cisplatin 238Paclitaxel 203Radiotherapy 195Pemetrexed 187Docetaxel 169Gemcitabine 157pembrolizumab 141Erlotinib Hydrochloride 107Etoposide 99Magnetic Resonance Spectroscopy 93Bevacizumab 91Specimen Handling 76Nivolumab 73Radiosurgery 72durvalumab 69Vinorelbine 54osimertinib 53Gefitinib 49Drug Therapy 49atezolizumab 42Irinotecan 42Radiation 40Topotecan 39Biopsy 39Standard of Care 38Cyclophosphamide 38Cetuximab 35Blood Specimen Collection 33Taxes 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Lung Neoplasms × salicylhydroxamic acid × Clear all
NCT07272057 2025-12-09

SGLT2 Inhibitors and Survival in Lung Cancer Patients With Diabetes

Shanghai Chest Hospital

Phase NA Not yet recruiting
200 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡